Massachusetts health insurers withdrew GLP-1 insurance coverage for weight loss this year, and 112,000 fewer commercially insured residents had a prescription covered. The state’s Health Policy Commission published the figures on 17 September 2026, a 52 percent fall from 2025. Coverage for diabetes prescriptions was not withdrawn.
What the Commission Measured
The comparison runs from 2025 to the first quarter of 2026, and it covers the commercial market in one American state. GLP-1 drugs are the class that includes semaglutide and tirzepatide, sold under names such as Ozempic, Wegovy and Zepbound, and prescribed both for type 2 diabetes and for weight loss.
Spending moved with the coverage. Gross spending on the drugs in the Massachusetts commercial market ran to more than $2.3 billion in 2025, or close to $1 billion net of rebates and discounts. Annualised 2026 spending is put at $662 million.
These are Massachusetts numbers. They describe what happened in one state’s commercial insurance market and do not set coverage rules anywhere else.
Which Plans Withdrew Weight-Loss Cover
Five payers are named in the Commission’s account, and they cover both private and public plans.
- Blue Cross Blue Shield of Massachusetts: ended blanket coverage of GLP-1 drugs for obesity.
- Point32Health: ended blanket coverage for obesity.
- Mass General Brigham Health Plan: ended blanket coverage for obesity.
- Group Insurance Commission: the body that buys cover for state employees discontinued it in July 2026.
- MassHealth: the state Medicaid programme discontinued it in July 2026.
From January, many commercial plans moved the benefit to an employer option, so an employer could buy weight-loss cover back for a higher charge. Reporting on the change indicates many chose not to.
How Far Use Fell at Each Payer
Utilisation fell at every payer named, but by very different amounts, and the size of the fall tracks how sweeping each decision was. The figures below are the share of members with a GLP-1 prescription, comparing the fourth quarter of 2025 with the first quarter of 2026.
| Payer | Q4 2025 | Q1 2026 |
|---|---|---|
| Blue Cross Blue Shield of Massachusetts | 6.1% | 3.7% |
| Point32Health | 6.5% | 3.3% |
| Health New England | 2.9% | 0.9% |
| Cigna | 1.7% | 1.6% |
| UnitedHealthcare | 1.0% | 0.9% |
This payer-level breakdown appears in the Commission’s report as summarised by GBH News and has not been repeated by other outlets, so it rests on a single published account of the underlying report.
What Is Still Covered
Diabetes prescriptions were left alone. Insurers in the state continue to cover GLP-1 drugs when they are prescribed to treat type 2 diabetes; what ended was blanket cover for the obesity indication.
That distinction decides who was affected. A member taking the same molecule under a diabetes diagnosis kept the benefit, while a member taking it for weight loss generally did not, unless their employer bought the option back.
What Patients Were Paying Before the Cuts
Cover is not the same as free, and the Commission’s figures show what members were contributing while the benefit existed. Across 2025, patient cost-sharing came to $45.9 million for diabetes prescriptions and $136.3 million for weight-loss prescriptions.
Per person, that worked out at about $66 a month on average for diabetes and $78 a month for weight loss. Averages are not individual bills: what any one member paid depended on their plan, deductible and pharmacy benefit.
With blanket cover gone, the alternative is the list price. Reporting on the Massachusetts change describes people paying hundreds of dollars a month out of pocket, though no published count says how many have done so.
Why the Insurers Moved
The stated reason is cost growth that outpaced everything around it. Spending on the drug class in Massachusetts grew at an average of 99.5 percent a year between 2019 and 2025, and insurers in the state attributed a run of losses to that growth.
The scale inside a single insurer’s drug budget shows why. CBS News Boston reported that GLP-1 products accounted for about 20 percent of Blue Cross Blue Shield of Massachusetts’s pharmacy spending, a figure drawn from the Commission’s work rather than an insurer disclosure.
What the State Expects Next
As of 22 September 2026, no Massachusetts insurer named in the report has announced that it will restore blanket weight-loss cover, and no state rule requires it. The benefit remains an employer purchasing decision in the commercial market.
The state’s own expectation is that prices fall. Health and Human Services Secretary Kiame Mahaniah has said he expects a major price crash within two years and a return to full coverage within two to three. That is a forecast by a state official, not a commitment by any insurer, and nothing has been filed to give it effect.
Members who want to know their own position should check their plan’s published formulary and their employer’s benefit documents, which are the only authoritative statement of what a particular policy covers.
Frequently Asked Questions
Has GLP-1 Insurance Coverage Ended Everywhere?
No. The Health Policy Commission’s report covers the commercial insurance market in Massachusetts only. Coverage rules for GLP-1 drugs are set plan by plan and differ by state, insurer, employer and country.
Are Diabetes Prescriptions Still Covered?
Yes. Insurers in Massachusetts continue to cover GLP-1 drugs prescribed to treat type 2 diabetes. What ended in 2026 was blanket coverage for the obesity, or weight-loss, indication.
How Many People Lost Coverage?
112,000 fewer commercially insured Massachusetts residents had a GLP-1 prescription covered for weight loss in the first quarter of 2026 than in 2025, a fall of 52 percent, according to the Commission’s report published on 17 September 2026.
Can an Employer Still Buy the Benefit?
In the Massachusetts commercial market, many plans made weight-loss cover an employer option from January 2026 at a higher charge. Whether it is available depends on the specific plan and employer.
How Much Did Spending Fall?
Net commercial spending on GLP-1 drugs in Massachusetts was close to $1 billion in 2025, against gross spending of more than $2.3 billion before rebates. Annualised 2026 spending is put at $662 million.
